Hospital
Bon Secours Mercy Health Franklin LLC
Bon Secours Mercy Health Franklin LLC was paid $8.68M by Medicaid between Jan 2020 and Dec 2024, across 151 billing codes. Its largest line is 99283, emergency room visit (moderate) — 31% of everything it billed.
33Billing provider infoBON SECOURS MERCY HEALTH FRANKLIN LLC
FRANKLIN, VA 23851
FRANKLIN, VA 23851
33aNPI1851936983assigned 11/13/2019
33bProvider typeGeneral Acute Care Hospital
28Total paid$8.68M
24GClaims215,343
24DCodes billed151
24AFirst – last monthJan 2020 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#52 of 80
Median peer was paid$14.69M
This provider vs. median0.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RALSTON, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 34,367 | $1.34M | |
| 2021 | 43,508 | $1.55M | |
| 2022 | 44,785 | $1.67M | |
| 2023 | 48,392 | $2.15M | |
| 2024incomplete | 44,291 | $1.97M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 31% | 16,073 | 13,670 | $2.71M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 9,583 | 7,967 | $1.55M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 5,594 | 4,658 | $957K |
| 96361 | Intravenous infusion, hydration; each additional hour | 5.3% | 1,851 | 1,482 | $457K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.2% | 2,882 | 2,461 | $455K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.4% | 8,245 | 1,851 | $382K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 3.5% | 1,211 | 1,030 | $304K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.5% | 2,060 | 1,725 | $300K |
| G0378 | Hospital observation service, per hour | 2.4% | 1,542 | 960 | $213K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.1% | 1,130 | 972 | $181K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.8% | 1,119 | 950 | $158K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.4% | 1,568 | 1,300 | $121K |
139 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.1% | 1,744 | $97K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,701 | $73K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,043 | $56K |
| 97162 | <1% | 363 | $49K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 322 | $40K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 831 | $40K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,365 | $39K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 244 | $35K |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,814 | $33K |
| 97161 | <1% | 364 | $31K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,347 | $28K |
| 80053 | Comprehensive metabolic panel | <1% | 9,001 | $24K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 155 | $24K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 837 | $23K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,196 | $20K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,682 | $19K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 848 | $16K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,725 | $14K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,132 | $13K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,389 | $11K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 609 | $10K |
| 83880 | <1% | 1,337 | $10K | |
| 87400 | <1% | 685 | $9K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 69 | $9K |
| 73630 | <1% | 494 | $9K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 14,010 | $8K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 13 | $8K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,544 | $7K |
| 73562 | <1% | 349 | $7K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,676 | $7K |
| 80061 | Lipid panel | <1% | 1,483 | $6K |
| 73610 | <1% | 201 | $6K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 495 | $5K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 463 | $5K |
| 83690 | <1% | 3,194 | $4K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 5,311 | $4K |
| 84484 | <1% | 6,654 | $4K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 169 | $4K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,199 | $4K |
| 73130 | <1% | 178 | $3K | |
| 81001 | <1% | 6,528 | $3K | |
| 85379 | <1% | 1,061 | $3K | |
| 83735 | <1% | 3,651 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,118 | $3K |
| 80076 | <1% | 613 | $3K | |
| 96376 | <1% | 1,188 | $3K | |
| 81025 | <1% | 3,052 | $3K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,820 | $3K |
| 73030 | <1% | 244 | $3K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,004 | $3K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 124 | $2K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,201 | $2K |
| 87807 | <1% | 455 | $2K | |
| 82607 | <1% | 449 | $2K | |
| 82962 | <1% | 3,334 | $2K | |
| 87070 | <1% | 1,843 | $2K | |
| 80050 | General health panel | <1% | 181 | $2K |
| 85027 | <1% | 976 | $2K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,528 | $2K |
| 83605 | <1% | 2,385 | $2K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 352 | $2K |
| 97016 | <1% | 46 | $2K | |
| 87040 | <1% | 564 | $1K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 510 | $1K |
| 70486 | <1% | 14 | $1K | |
| 86756 | <1% | 52 | $1K | |
| 81003 | <1% | 2,044 | $1K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 175 | $1K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 13 | $1K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 352 | $1K |
| 86803 | <1% | 123 | $1K | |
| 82077 | <1% | 1,137 | $834.98 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 101 | $818.47 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,258 | $782.11 |
| 84703 | <1% | 268 | $774.62 | |
| 85378 | <1% | 103 | $675.39 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 263 | $615.33 |
| 80179 | <1% | 97 | $552.60 | |
| 72100 | <1% | 19 | $503.85 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 130 | $502.66 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 522 | $446.31 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 990 | $427.64 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 96 | $367.99 |
| 99218 | <1% | 14 | $358.24 | |
| 73110 | <1% | 17 | $349.81 | |
| 80143 | <1% | 97 | $345.40 | |
| 85610 | <1% | 1,131 | $341.56 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 42 | $314.02 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 13 | $302.70 |
| 74018 | <1% | 16 | $301.74 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 681 | $288.38 |
| 97116 | <1% | 30 | $285.27 | |
| 73502 | <1% | 50 | $268.47 | |
| 82553 | <1% | 250 | $262.63 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 281 | $244.77 |
| 73560 | <1% | 35 | $234.34 | |
| 84145 | <1% | 38 | $168.60 | |
| 93356 | <1% | 177 | $150.61 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 571 | $120.00 |
| 36600 | <1% | 13 | $103.22 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 32 | $93.00 |
| 82570 | <1% | 72 | $84.06 | |
| 87077 | <1% | 173 | $82.11 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,272 | $70.40 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 673 | $63.94 |
| 87186 | <1% | 195 | $62.86 | |
| 83540 | <1% | 27 | $55.92 | |
| 82550 | <1% | 394 | $51.13 | |
| 84466 | <1% | 13 | $33.83 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 447 | $28.19 |
| 86850 | <1% | 12 | $21.88 | |
| 86900 | <1% | 43 | $20.18 | |
| J3490 | Unclassified drugs | <1% | 1,257 | $19.82 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 156 | $18.53 |
| 82803 | <1% | 30 | $18.03 | |
| 84702 | <1% | 18 | $15.58 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 178 | $13.99 |
| 87210 | <1% | 164 | $11.90 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 425 | $11.41 |
| 86901 | <1% | 43 | $10.09 | |
| 83874 | <1% | 52 | $10.04 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 72 | $6.98 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 103 | $5.42 |
| 85730 | <1% | 15 | $4.21 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 108 | $3.76 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 20 | $3.53 |
| 87147 | 0% | 94 | $0.00 | |
| 74022 | 0% | 28 | $0.00 | |
| 94761 | 0% | 214 | $0.00 | |
| 94760 | 0% | 17 | $0.00 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 0% | 94 | $0.00 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 0% | 12 | $0.00 |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | 0% | 144 | $0.00 |
| 73140 | 0% | 13 | $0.00 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 86 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 14 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 56 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 26 | $0.00 |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRALSTON, KIMBERLY (SYSTEM DIRECTOR)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.